EMA Approval: Jonexa

Jonexa (hylastan) is a bacterially fermented product derived from hyaluronan that is indicated for the treatment of pain associated with OA of the knee and administered in one or two injections. Genzyme expects to launch Jonexa in select European Union markets and Hong Kong in 2010 because they believe opportunity exists in those markets for a lower cost, more convenient OA treatment option than locally available multiple injection products.

For more information about recent drug approvals or pharmaceutical branding, please contact Vince Budd at vbudd@addisonwhitney.com